ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (Stock Code: 01541.HK) successfully listed on the Main Board of the Hong Kong Stock Exchange on September 5, 2023, with an issuance price of HKD 18.60 per share and net proceeds of approximately HKD 225 million. Key cornerstone investors, including Harvest Fund, WuXi Biologics, RemeGen, and ClinChoice, were introduced.

As the joint sponsors' onshore legal advisor for the listing, Jingtian & Gongcheng's legal team participated throughout the entire project, and provided high-quality and professional legal services, receiving unanimous acclaim from the client and all stakeholders.